PART I Overview Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology. Our therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc. (Certainty)....
Q2 FY2026 — expected 2026-09-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-01-12 | 2025-10-31 | 0001493152-26-001845 | EDGAR | 40K words |
| 2025-01-10 | 2024-10-31 | 0001493152-25-001787 | EDGAR | — |
| 2024-01-16 | 2023-10-31 | 0001493152-24-002453 | EDGAR | — |
| 2023-01-04 | 2022-10-31 | 0001493152-23-000346 | EDGAR | — |
| 2022-01-04 | 2021-10-31 | 0001493152-22-000302 | EDGAR | — |
| 2021-01-07 | 2020-10-31 | 0001493152-21-000456 | EDGAR | — |
| 2020-01-09 | 2019-10-31 | 0001513162-20-000009 | EDGAR | — |
| 2019-01-11 | 2018-10-31 | 0001513162-19-000016 | EDGAR | — |
| 2018-01-09 | 2017-10-31 | 0001513162-18-000006 | EDGAR | — |
| 2016-12-07 | 2016-10-31 | 0001513162-16-001096 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2026-01-31 | 0001493152-26-009370 | EDGAR | 15K words |
| 2025-09-10 | 2025-07-31 | 0001493152-25-013000 | EDGAR | — |
| 2025-05-28 | 2025-04-30 | 0001641172-25-012701 | EDGAR | — |
| 2025-03-11 | 2025-01-31 | 0001493152-25-009854 | EDGAR | — |
| 2024-09-06 | 2024-07-31 | 0001493152-24-035335 | EDGAR | — |
| 2024-06-04 | 2024-04-30 | 0001493152-24-022573 | EDGAR | — |
| 2024-03-12 | 2024-01-31 | 0001493152-24-009683 | EDGAR | — |
| 2023-09-06 | 2023-07-31 | 0001493152-23-031826 | EDGAR | — |
| 2023-06-14 | 2023-04-30 | 0001493152-23-021271 | EDGAR | — |
| 2023-03-17 | 2023-01-31 | 0001493152-23-007994 | EDGAR | — |
| 2022-09-09 | 2022-07-31 | 0001493152-22-025490 | EDGAR | — |
| 2022-06-10 | 2022-04-30 | 0001493152-22-016452 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001493152-26-009699 | EDGAR | 1K words |
| 2026-02-09 | 0001493152-26-005702 | EDGAR | — |
| 2025-12-12 | 0001493152-25-027321 | EDGAR | — |
| 2025-03-21 | 0001493152-25-011151 | EDGAR | — |
| 2024-11-08 | 0001493152-24-044224 | EDGAR | — |
| 2024-05-08 | 0001493152-24-018170 | EDGAR | — |
| 2024-03-22 | 0001493152-24-010995 | EDGAR | — |
| 2023-12-07 | 0001493152-23-043932 | EDGAR | — |
| 2023-04-17 | 0001493152-23-012483 | EDGAR | — |
| 2023-03-10 | 0001493152-23-007172 | EDGAR | — |
309 total filings indexed. 277 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000715446 |
| Ticker | ANIX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.anixa.com |
| Listed | 1983-10-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report